Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.

Folefac AminkengColin J D RossShahrad R RassekhSoomi HwangMichael J RiederAmit P BhavsarAnne SmithShubhayan SanataniKaren A GelmonDaniel BernsteinMichael R HaydenUrsula AmstutzBruce C Carletonnull null

Published in: British journal of clinical pharmacology (2016)

Existing evidence demonstrates that genetic factors have the potential to improve the discrimination between individuals at higher and lower risk of ACT. Genetic testing may therefore support both patient care decisions and evidence development for an improved prevention of ACT.

Keyphrases

high glucose
risk factors
diabetic rats
clinical practice
copy number
drug induced
risk assessment
endothelial cells
dna methylation
climate change